If you are a journalist and are interested in one of the nationally prioritised studies listed below, please contact the Press Office of the funding organisation.
This study is designed to allow families of immunosuppressed children and young people to self-record their experiences of COVID-19 and other viral respiratory illnesses during the COVID-19 epidemic.
Published: 03 April 2020
The primary objective is to assess the safety of a single intravenous infusion of MSCs in patients with ARDS due to COVID-19.
Published: 03 April 2020
Our genes determine how susceptible we are to life-threatening infection. When a patient is already sick, different genetic factors determine how likely they are to survive.The GenOMICC (Genetics of Susceptibility and Mortality in Critical Care) study will identify the specific genes that cause some people to be susceptible to specific infections and consequences of severe injury.
Published: 03 April 2020
The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed.
Published: 03 April 2020
A five year project that seeks to improve diagnosis of infectious and inflammatory illness in patients of all ages, through development of diagnostic tests based on host gene expression responses.
Published: 03 April 2020
A randomised controlled trial for patients admitted to the intensive care unit (ICU) with severe Community-Acquired Pneumonia (CAP). This trial studies a number of different treatment categories under one platform with an aim to determine the best package of treatment for patients.
Published: 01 April 2020
The trial aims to give a rapid answer about the effectiveness of hydroxychloroquine in modifying the disease course of COVID-19.
Published: 01 April 2020
An adaptive, randomised, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. The study is a multicentre trial that will be conducted in up to approximately 75 sites globally.
Published: 01 April 2020
A randomised, double-blind, placebo-controlled, multicentre study to evaluate the safety and efficiacy of Tocilizumab in patients with severe COVID-19 pneumonia
Published: 30 March 2020
Pandemic Respiratory Infection Emergency System Triage (previously: The PAINTED study: Pandemic Influenza Triage in the Emergency Department)
Published: 30 March 2020
Maternal and Perinatal Outcomes of Pandemic Influenza in Pregnancy
Published: 30 March 2020
Real time refinement and validation of criteria and tools used in primary care to aid hospital referral decisions for patients of all ages in the event of surge during an influenza pandemic.
Published: 30 March 2020
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
Published: 30 March 2020
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19
Published: 30 March 2020
The researchers will test a library of approximately 1,000 drugs already approved for use in humans on cells in the laboratory to determine if any can reduce the toxic effects of novel coronavirus infection.
Published: 25 March 2020
The researchers will collect samples and data from COVID-19 patients in the UK to answer many urgent questions about the virus in real time.
Published: 25 March 2020
Researchers at University of Oxford are in the process of developing a coronavirus vaccine called ChAdOx1 nCoV-19.
Published: 25 March 2020
Rapid development of manufacturing processes for future production of adenovirus-vectored COVID19 vaccine at million-dose scale
Published: 25 March 2020
The researchers will develop antibodies that target the novel coronavirus with the aim of developing a new therapy for Covid-19.
Published: 25 March 2020